1. Home
  2. MNY vs LUNG Comparison

MNY vs LUNG Comparison

Compare MNY & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$1.31

Market Cap

58.9M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.53

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
LUNG
Founded
2014
1995
Country
Singapore
United States
Employees
240
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MNY
LUNG
Price
$1.31
$1.53
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$4.00
$5.38
AVG Volume (30 Days)
20.4K
393.9K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
$19.58
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.66
$1.13
52 Week High
$2.40
$3.88

Technical Indicators

Market Signals
Indicator
MNY
LUNG
Relative Strength Index (RSI) 46.45 53.50
Support Level $1.31 $1.36
Resistance Level $1.52 $1.64
Average True Range (ATR) 0.04 0.12
MACD -0.00 0.01
Stochastic Oscillator 38.46 57.78

Price Performance

Historical Comparison
MNY
LUNG

About MNY MoneyHero Limited

MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: